This could imply screening is connected with improved survival; nevertheless, the potential effect of lead-period bias and of the fairly small samples must be considered. All privileges reserved. Neither of the parties endorse or suggest any commercial products, services, or equipment.. BRCA2 mutations herald poor prognosis in screen-detected prostate cancer By Joanna Lyford, Senior medwireNews Reporter Among men with prostate cancer tumor detected on screening, survival among people that have a mutation in the BRCA2 gene is a lot poorer than in those without such a mutation, researchers report. BRCA2 mutations are recognized to confer an elevated risk for developing prostate tumor and to be connected with more intense tumours.Better cancers outcomes start out with more accurate and earlier detection, said Karri Ballard, Ph.D., RBM’s director of diagnostic initiatives. Advanced prognostic and companion diagnostic lab tests are on the minds of clinicians, patients and administrators, who all desire effective and efficient equipment to help save lives. Related StoriesStudy shows rare HER2 missense mutations usually do not spread breast cancer on their ownNew antenna-like device makes breast cancer medical procedures much easier for surgeonsMD Anderson study reveals why chemotherapy drugs not effective for many pancreatic cancer individuals The CPRIT was created to purchase the people and tasks that will look for a cure for cancer, said Jimmy Mansour, the Institute’s oversight committee chairman.